FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387428709> ?p ?o ?g. }

• W4387428709 abstract "Palovarotene is under development for the treatment of fibrodysplasia ossificans progressiva (FOP). The objectives of this study were to evaluate palovarotene pharmacokinetics under fed versus fasted conditions and its induction potential towards cytochrome P450 3A4 (CYP3A4) substrate, midazolam. In this phase I, open-label trial (NCT04829773), palovarotene pharmacokinetics were characterized after repeated once-daily dosing. In one cohort, healthy participants received three doses of palovarotene 20 mg on Days 1, 6, and 11, as whole capsules under fasted or fed conditions, or sprinkled on food under fed conditions. In another cohort, individuals received midazolam 2 mg on Days 1 and 15 and a daily dose of palovarotene 20 mg on Days 2–15. Palovarotene and midazolam pharmacokinetics, including area under the concentration-time curve from time zero to infinity (AUC(0–∞)) and maximum observed plasma drug concentration (Cmax), were assessed. Adverse events (AEs) were recorded. Overall, 23 participants completed each part. Palovarotene Cmax and AUC(0–∞) increased by 16.5% and 39.7% under fed versus fasted conditions. Pharmacokinetics were comparable between the whole capsule and sprinkled on food, under fed conditions. Midazolam AUC(0–∞) and Cmax decreased by 13.3% and 9.7% upon palovarotene co-administration over 14 days, less than that required to be considered a weak CYP3A4 inducer. Plasma palovarotene exposures were comparable after single and multiple doses. No serious AEs were reported. These data support palovarotene administration after a meal, as a whole capsule or sprinkled on food. Palovarotene at 20 mg/day is a not a clinical inducer of CYP3A4. These results provide insights into palovarotene pharmacokinetics, aiding optimization of administration for patients with FOP. NCT04829773. Fibrodysplasia ossificans progressiva, also known as FOP, is a very rare genetic condition where bone forms in places it is not usually found, such as in the muscles, tendons, and ligaments. Retinoids are molecules that the body produces from vitamin A to aid normal bone development. Palovarotene is a therapeutic retinoid that has been developed for the treatment of FOP. This article describes a clinical trial where people without FOP received oral palovarotene to determine how it is absorbed and broken down (metabolized) by the body when taken after a meal or after fasting (a period of not eating) as a whole capsule or when sprinkled on food. The trial also examined how palovarotene might interact with other treatments that are broken down by the body in the same way as palovarotene. The trial found that the amount of palovarotene that circulates in the blood increased more when taken after a meal compared with after fasting. Palovarotene was metabolized by the body in a similar way when taken as a whole capsule or when sprinkled on food. This finding is important as some people with FOP have difficulty swallowing. At a 20 mg dose, palovarotene was unlikely to interact with other treatments that are metabolized in the same way. No serious side effects were reported. These results show that palovarotene should be taken after a meal, either as a whole capsule or sprinkled on food." @default.
• W4387428709 created "2023-10-08" @default.
• W4387428709 creator A5031856520 @default.
• W4387428709 creator A5043155346 @default.
• W4387428709 creator A5048959398 @default.
• W4387428709 creator A5056242932 @default.
• W4387428709 date "2023-10-07" @default.
• W4387428709 modified "2023-10-09" @default.
• W4387428709 title "The Pharmacokinetic Profile of Palovarotene: An Open-Label Phase I Trial Investigating the Effect of Food and Potential for Drug–Drug Interaction in Healthy Participants" @default.
• W4387428709 cites W1554949593 @default.
• W4387428709 cites W162302372 @default.
• W4387428709 cites W1908563203 @default.
• W4387428709 cites W1972553581 @default.
• W4387428709 cites W2000180872 @default.
• W4387428709 cites W2008915544 @default.
• W4387428709 cites W2047943851 @default.
• W4387428709 cites W2052886229 @default.
• W4387428709 cites W2067240929 @default.
• W4387428709 cites W2084194647 @default.
• W4387428709 cites W2088295232 @default.
• W4387428709 cites W2104389955 @default.
• W4387428709 cites W2109216177 @default.
• W4387428709 cites W2189005902 @default.
• W4387428709 cites W2338632102 @default.
• W4387428709 cites W2627047415 @default.
• W4387428709 cites W2768533515 @default.
• W4387428709 cites W2893567000 @default.
• W4387428709 cites W2980140195 @default.
• W4387428709 cites W4286213849 @default.
• W4387428709 cites W4292528167 @default.
• W4387428709 cites W4297199173 @default.
• W4387428709 cites W4321350999 @default.
• W4387428709 doi "https://doi.org/10.1007/s13318-023-00856-2" @default.
• W4387428709 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37804430" @default.
• W4387428709 hasPublicationYear "2023" @default.
• W4387428709 type Work @default.
• W4387428709 citedByCount "0" @default.
• W4387428709 crossrefType "journal-article" @default.
• W4387428709 hasAuthorship W4387428709A5031856520 @default.
• W4387428709 hasAuthorship W4387428709A5043155346 @default.
• W4387428709 hasAuthorship W4387428709A5048959398 @default.
• W4387428709 hasAuthorship W4387428709A5056242932 @default.
• W4387428709 hasBestOaLocation W43874287091 @default.
• W4387428709 hasConcept C109650736 @default.
• W4387428709 hasConcept C112705442 @default.
• W4387428709 hasConcept C126322002 @default.
• W4387428709 hasConcept C197934379 @default.
• W4387428709 hasConcept C22979827 @default.
• W4387428709 hasConcept C2776814716 @default.
• W4387428709 hasConcept C2777288759 @default.
• W4387428709 hasConcept C2778000748 @default.
• W4387428709 hasConcept C2781245242 @default.
• W4387428709 hasConcept C526171541 @default.
• W4387428709 hasConcept C62231903 @default.
• W4387428709 hasConcept C71924100 @default.
• W4387428709 hasConcept C76318530 @default.
• W4387428709 hasConcept C98274493 @default.
• W4387428709 hasConceptScore W4387428709C109650736 @default.
• W4387428709 hasConceptScore W4387428709C112705442 @default.
• W4387428709 hasConceptScore W4387428709C126322002 @default.
• W4387428709 hasConceptScore W4387428709C197934379 @default.
• W4387428709 hasConceptScore W4387428709C22979827 @default.
• W4387428709 hasConceptScore W4387428709C2776814716 @default.
• W4387428709 hasConceptScore W4387428709C2777288759 @default.
• W4387428709 hasConceptScore W4387428709C2778000748 @default.
• W4387428709 hasConceptScore W4387428709C2781245242 @default.
• W4387428709 hasConceptScore W4387428709C526171541 @default.
• W4387428709 hasConceptScore W4387428709C62231903 @default.
• W4387428709 hasConceptScore W4387428709C71924100 @default.
• W4387428709 hasConceptScore W4387428709C76318530 @default.
• W4387428709 hasConceptScore W4387428709C98274493 @default.
• W4387428709 hasFunder F4320328455 @default.
• W4387428709 hasLocation W43874287091 @default.
• W4387428709 hasLocation W43874287092 @default.
• W4387428709 hasOpenAccess W4387428709 @default.
• W4387428709 hasPrimaryLocation W43874287091 @default.
• W4387428709 hasRelatedWork W1647379185 @default.
• W4387428709 hasRelatedWork W1977492939 @default.
• W4387428709 hasRelatedWork W1981709770 @default.
• W4387428709 hasRelatedWork W2041757618 @default.
• W4387428709 hasRelatedWork W2050475902 @default.
• W4387428709 hasRelatedWork W2058763162 @default.
• W4387428709 hasRelatedWork W2323480349 @default.
• W4387428709 hasRelatedWork W2327615024 @default.
• W4387428709 hasRelatedWork W4309043937 @default.
• W4387428709 hasRelatedWork W2102995206 @default.
• W4387428709 isParatext "false" @default.
• W4387428709 isRetracted "false" @default.
• W4387428709 workType "article" @default.